Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting

NCT01161173 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01161173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01161173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Completed
Start date
April 30, 2008
Completion date
August 31, 2012
Enrollment
347 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

nonsquamous nonsmall cell neoplasm of lung